{"id":639,"date":"2015-07-24T17:42:32","date_gmt":"2015-07-24T12:12:32","guid":{"rendered":"https:\/\/delveinsightblog.wordpress.com\/?p=639"},"modified":"2025-05-05T17:20:20","modified_gmt":"2025-05-05T11:50:20","slug":"oral-mucositis-pipeline-insights-2015-a-delveinsight-report","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/oral-mucositis-pipeline-insights-2015-a-delveinsight-report","title":{"rendered":"Oral Mucositis Pipeline Insights, 2015- A DelveInsight Report"},"content":{"rendered":"<p>In current scenario chemotherapies and radiations are prominently used to cure cancer which results in adverse effects. Oral Mucositis\u00a0is one such adverse effect that results in ulceration\u00a0in the mouth due to high dosage of chemotherapy. The patients undergoing head and neck cancer chemotherapy are at a high risk of developing <strong>oral mucositis with mean incidence of 80-100%.<\/strong><\/p>\n<p>It is estimated that <strong>89.0%-100.0% of the population undergoing head and neck chemotherapy<\/strong> will develop oral mucositis. In addition there are <strong>&gt;4M stage 3-4 cancer patients worldwide (&gt;1m in U.S.) <\/strong>that are receiving high doses of CT or a combination of <strong>CT\/RT that develop OM 1.0%-53.0%<\/strong> of the time.<\/p>\n<p>The current status of Oral mucositis (OM) treatment includes basic <strong>oral care, cryotherapy, topical rinses such as lidocaine and carbomer and palifermin, and a growth factor.<\/strong> None of these products have been completely successful in treating OM and a high unmet medical need exists.<\/p>\n<p><strong>DelveInsight<\/strong> report on Oral Mucositis gives comparative study of drugs under development. The report provides assessment of <strong>AG-013 pipeline drug by ActogeniX NV (Intrexon)<\/strong> which is in <strong>Phase II\/III.<\/strong> In addition to this, the report imparts information on several other drugs as well, among which <strong>6 are in phase II, 3 in phase I, 3 in pre &#8211; clinical and 1 in discovery phase<\/strong>.<\/p>\n<p><img decoding=\"async\" class=\"alignnone  wp-image-641\" src=\"https:\/\/delveinsightblog.files.wordpress.com\/2015\/07\/hyyyyyyyyyyyyyyyttttttttttttttttttttttttttttttttttttttttttttttttttttttttttt.jpg?w=300\" alt=\"hyyyyyyyyyyyyyyyttttttttttttttttttttttttttttttttttttttttttttttttttttttttttt\" width=\"492\" height=\"301\" \/><\/p>\n<p><strong>Key highlights of the report<\/strong><\/p>\n<ul>\n<li>R&amp;D activities and technologies used along with the pipeline molecules in development.<\/li>\n<li>Information related to collaborations, in-licensing and out-licensing deals.<\/li>\n<li>Stages of development of pipeline molecules.<\/li>\n<li>Therapeutic assessments by molecule types, route of administration, monotherapy and combination products.<\/li>\n<\/ul>\n<p>The Oral Mucositis-Pipeline Insights, 2015 Report envisages <strong>Pipeline Intelligence<\/strong> by identifying the key players along with their <strong>potential pipeline molecule<\/strong>. Therefore DelveInsight\u2019s report on Oral Mucositis-Pipeline Insights helps to <strong>optimize portfolio by creating effective counter-strategies to gain competitive and therapeutic advantage in global Pharma market.<\/strong><\/p>\n<p>DelveInsight is offering the Report at a price of <em><strong>USD 1,250<\/strong><\/em> as a single user license, <em><strong>USD 2,500<\/strong> <\/em>as a site license and <em><strong>USD 4,000<\/strong><\/em> as a Global\/Enterprise License.<\/p>\n<p>For more information on Oral Mucositis-Pipeline\u00a0Insight Report, email at <a href=\"mailto:info@delveInsight.com\">info@delveInsight.com<\/a><\/p>\n<p><strong>About Us<\/strong><\/p>\n<p>DelveInsight is a leading Business Consulting and Market Research Firm.\u00a0 We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing <em><strong>custom research services in coherence with interest area of the clients.<\/strong><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>In current scenario chemotherapies and radiations are prominently used to cure cancer which results in adverse effects. Oral Mucositis\u00a0is one such adverse effect that results in ulceration\u00a0in the mouth due to high dosage of chemotherapy. The patients undergoing head and neck cancer chemotherapy are at a high risk of developing oral mucositis with mean incidence [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[84,134,137,173,180],"industry":[17225],"therapeutic_areas":[17260,17228],"class_list":["post-639","post","type-post","status-publish","format-standard","hentry","category-articles","tag-api","tag-business-consultant","tag-cancer","tag-collaborations","tag-competitive-landscape","industry-pharmaceutical","therapeutic_areas-dental-and-oral-health","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Oral Mucositis Pipeline Insights, 2015 by DelveInsight<\/title>\n<meta name=\"description\" content=\"The current status of Oral mucositis treatment includes basic oral care, cryotherapy, topical rinses such as lidocaine and carbomer and...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/oral-mucositis-pipeline-insights-2015-a-delveinsight-report\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oral Mucositis Pipeline Insights, 2015 by DelveInsight\" \/>\n<meta property=\"og:description\" content=\"The current status of Oral mucositis treatment includes basic oral care, cryotherapy, topical rinses such as lidocaine and carbomer and...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/oral-mucositis-pipeline-insights-2015-a-delveinsight-report\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-07-24T12:12:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-05T11:50:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/delveinsightblog.files.wordpress.com\/2015\/07\/hyyyyyyyyyyyyyyyttttttttttttttttttttttttttttttttttttttttttttttttttttttttttt.jpg?w=300\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Oral Mucositis Pipeline Insights, 2015 by DelveInsight","description":"The current status of Oral mucositis treatment includes basic oral care, cryotherapy, topical rinses such as lidocaine and carbomer and...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/oral-mucositis-pipeline-insights-2015-a-delveinsight-report","og_locale":"en_US","og_type":"article","og_title":"Oral Mucositis Pipeline Insights, 2015 by DelveInsight","og_description":"The current status of Oral mucositis treatment includes basic oral care, cryotherapy, topical rinses such as lidocaine and carbomer and...","og_url":"https:\/\/www.delveinsight.com\/blog\/oral-mucositis-pipeline-insights-2015-a-delveinsight-report","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2015-07-24T12:12:32+00:00","article_modified_time":"2025-05-05T11:50:20+00:00","og_image":[{"url":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/07\/hyyyyyyyyyyyyyyyttttttttttttttttttttttttttttttttttttttttttttttttttttttttttt.jpg?w=300","type":"","width":"","height":""}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/oral-mucositis-pipeline-insights-2015-a-delveinsight-report","url":"https:\/\/www.delveinsight.com\/blog\/oral-mucositis-pipeline-insights-2015-a-delveinsight-report","name":"Oral Mucositis Pipeline Insights, 2015 by DelveInsight","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/oral-mucositis-pipeline-insights-2015-a-delveinsight-report#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/oral-mucositis-pipeline-insights-2015-a-delveinsight-report#primaryimage"},"thumbnailUrl":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/07\/hyyyyyyyyyyyyyyyttttttttttttttttttttttttttttttttttttttttttttttttttttttttttt.jpg?w=300","datePublished":"2015-07-24T12:12:32+00:00","dateModified":"2025-05-05T11:50:20+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The current status of Oral mucositis treatment includes basic oral care, cryotherapy, topical rinses such as lidocaine and carbomer and...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/oral-mucositis-pipeline-insights-2015-a-delveinsight-report"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/oral-mucositis-pipeline-insights-2015-a-delveinsight-report#primaryimage","url":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/07\/hyyyyyyyyyyyyyyyttttttttttttttttttttttttttttttttttttttttttttttttttttttttttt.jpg?w=300","contentUrl":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/07\/hyyyyyyyyyyyyyyyttttttttttttttttttttttttttttttttttttttttttttttttttttttttttt.jpg?w=300"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":null,"coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">API<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Business Consultant<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">collaborations<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Competitive landscape<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">API<\/span>","<span class=\"advgb-post-tax-term\">Business Consultant<\/span>","<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">collaborations<\/span>","<span class=\"advgb-post-tax-term\">Competitive landscape<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 11 years ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Jul 24, 2015","modified":"Updated on May 5, 2025"},"absolute_dates_time":{"created":"Posted on Jul 24, 2015 5:42 pm","modified":"Updated on May 5, 2025 5:20 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/639","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=639"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/639\/revisions"}],"predecessor-version":[{"id":31670,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/639\/revisions\/31670"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=639"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=639"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=639"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=639"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=639"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}